NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02182778,GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer,https://clinicaltrials.gov/study/NCT02182778,,COMPLETED,To validate the superiority of Gemcitabine/Cisplatin/S-1 over Gemcitabine/Cisplatin for unresectable biliary tract cancer.,NO,Biliary Tract Cancer,DRUG: Gemcitabine/Cisplatin|DRUG: Gemcitabine/Cisplatin /S-1,"Overall survival rate, The primary endpoint is designated to evaluate overall survival rate at 12-month., Probability of 1-year survival (%)","Response rate, The investigators will conduct CT test every 3 months in order to measure the tumor size of each patient and evaluate the best tumor response according to RECIST criteria., Every 3 months, up to 24 months|Progression free survival, In oredr to research the progression survival, the investigators will check the presence of progression disease for each patient every three months., Every 3 months, up to 24 months|Number of Participants with Adverse Events as a Measure of Safety, The investigators will examine the frequency and the degree of each side effect that will appear to the patient at each course of chemotherapy ., 24 months",,Kansai Hepatobiliary Oncology Group,,ALL,"ADULT, OLDER_ADULT",PHASE3,246,NETWORK,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,KHBO1401|UMIN 000014371,2014-07-09,2016-02-04,2018-04-16,2014-07-08,,2019-02-21,"Kyoto University Hospital, Kyoto, 606-8507, Japan",
